Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603299 | 0.82 | CA2 (0.54) | CA1CA2CYP2A6SMN1; SMN2CA12 | |
| SCHEMBL8290973 | 0.79 | CYP2A6 (0.60) | CA1CA2CYP2A6SMN1; SMN2ALDH1A1 | |
| SCHEMBL3403576 | 0.78 | CA2 (0.52) | CA1CA2CYP2A6SMN1; SMN2CA12 | |
| SCHEMBL4277592 | 0.74 | CA2 (0.45) | CA1CA2CYP2A6SMN1; SMN2CA12 | |
| SCHEMBL21400131 | 0.74 | CYP2A6 (0.54) | CA1CA2CYP2A6SMN1; SMN2ALDH1A1 | |
| SCHEMBL91157 | 0.73 | CYP2A6 (0.67) | CA1CA2CYP2A6SMN1; SMN2ALDH1A1 | |
| SCHEMBL1273504 | 0.72 | CYP2A6 (0.56) | CA1CA2CYP2A6SMN1; SMN2CA12 | |
| SCHEMBL29425310 | 0.72 | CA2 (1.00) | CA1CA2CYP2A6CA12CA9 | |
| SCHEMBL4243562 | 0.72 | CA2 (1.00) | CA1CA2CYP2A6CA12CA9 | |
| SCHEMBL23032162 | 0.71 | SMN1; SMN2 (0.50) | CA1CA2CYP2A6SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | STS, SULT2A1, SULT1A1 | CA1 449/4885CA2 1316/4885CYP2A6 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.